All Updates

All Updates

icon
Filter
Earnings/results
Elevation Oncology misses analyst consensus; reports wider net losses for Q4 2022 and full-year
Precision Medicine
Mar 9, 2023
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

Mar 9, 2023

Elevation Oncology misses analyst consensus; reports wider net losses for Q4 2022 and full-year

Earnings/results

  • Elevation Oncology reported a net loss per share of USD 0.82 in Q4 2022, missing analyst expectations by 5.1%. Net loss for the quarter increased significantly by 97.9% YoY to USD 19 million. Net losses for the full financial year 2022 also worsened by almost 2x YoY to USD 95.1 million. Elevation Oncology is a clinical-stage company that does not generate any drug sales.  

  • The significant increase in net losses for Q4 2022 was mainly attributable to the increase in R&D expenses which rose by more than 2x YoY, primarily due to seribantumab manufacturing and clinical trial expenses. Further, administration costs increased by 17.6% to USD 4 million due to an increase in personnel costs. 

  • The company expects to achieve a few milestones for 2023 which include: 1) plans to present preclinical proof-of-concept data of EO-3021 at a medical conference in 1H 2023 and 2) expects to initiate Phase I clinical trial of EO-3021 in the US in 2H 2023. 

  • Cash and cash equivalents stood at USD 90.3 million at the end of December 2022, decreasing from USD 107.9 million in September 2022. It expects to extend its cash runway till 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.